Lung Cancer News and Research

Latest Lung Cancer News and Research

NSCLC drug regimen approved in 2006 does not improve survival for older patients

Analysis of a drug regimen approved by the F.D.A. in 2006 for the treatment of non-small cell lung cancer (bevacizumab added to the standard chemotherapy regimen carboplatin and paclitaxel) finds Medicare insured patients age 65 years and older who received this regimen did not have improved survival compared to patients who received the standard treatment of carboplatin and paclitaxel alone, according to a study in the April 18 issue of JAMA.

18 Apr 2012

Bevacizumab added to chemotherapy for NSCLC does not improve survival in elderly patients

Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) - an approach approved by the FDA in 2006 - did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare, a new study by Dana-Farber Cancer Institute researchers has found.

18 Apr 2012

Idera commences IMO-3100 Phase 2 clinical trial for psoriasis

Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.

18 Apr 2012

FDA grants 510(k) clearance for QIAGEN’s molecular detection PCR technology

QIAGEN N.V. today announced that the U.S. Food and Drug Administration (FDA) has granted two 510(k) clearances for its real-time PCR (polymerase chain reaction) instrument Rotor-Gene Q MDx and a compatible test for the detection of Influenza A/B, the artus Infl A/B RG RT-PCR Kit, for in vitro diagnostic use.

From QIAGEN Manchester Limited 17 Apr 2012

Merck, Endocyte enter vintafolide development and commercialization agreement

Merck, known as MSD outside the United States and Canada, and Endocyte Inc., today announced that they have entered into an agreement to develop and commercialize Endocyte's novel investigational therapeutic candidate vintafolide (EC145).

16 Apr 2012

Study calls for research into all aspects of follow-up care in lung cancer

Scientist say there is an urgent need for research into all aspects of follow-up care in lung cancer. The study presented in the May 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology focused on different follow-up strategies for patients with lung cancer.

16 Apr 2012

CT guided transthoracic fine needle aspiration might diagnose pulmonary nodules

Screening for lung cancer with low dose CT scans has been shown to save lives. However, research shows that when CT scans reveal nodules in the lungs, it is not cancerous 96 percent of the time. As a result, scientists are looking for ways to more accurately make a diagnosis. One way is by using a CT guided transthoracic fine needle aspiration.

16 Apr 2012

Researchers discover new class of molecular mutation in breast cancer

Mayo Clinic researchers have discovered a new class of molecular mutation in various forms of breast cancer, a finding that may shed new light on development and growth of different types of breast tumors. Called fusion transcripts, the mutated forms of RNA may also provide a way to identify tumor subtypes and offer new strategies to treat them, investigators say.

16 Apr 2012

Study investigates genetic factors and smoking exposure in Japanese lung cancer patients

Previous research has shown that Asian patients with lung cancer are more likely to harbor epidermal growth factor receptor (EGFR) mutations. Furthermore, Asian patients with lung cancer are more likely to be non-smokers than Western patients with lung cancer. Research in the May 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology goes deeper, investigated genetic factors and smoking exposure in Japanese lung cancer patients.

16 Apr 2012

Lung cancer rates continue to rise among UK women

Lung cancer cases continue to rise in women with more than 18,000 UK women diagnosed with the disease in 2009 according to the latest Cancer Research UK figures released today.

16 Apr 2012

Mayo Clinic experts available to discuss mental health challenges faced by cancer survivors

April is National Cancer Control Month, which focuses on the prevention, detection, and treatment of cancer and on efforts to improve the quality of life of the more than 11 million cancer survivors in the United States.

12 Apr 2012

Research explores power of offering colon cancer screening options

Researchers find that when given a choice of methods, more people will opt to get screened for colon cancer. Meanwhile, a separate study found that insurance coverage of lung cancer screenings for high-risk patients could prevent -- at a low cost -- thousands of deaths annually.

12 Apr 2012

Lung cancer screening could be cost effective: Study finds

A new study shows that screening longtime tobacco users for lung cancer would be less costly than the widely accepted practice of screening for breast, cervical and colorectal cancers and would reduce the death toll of lung cancer by an estimated 15,000 lives a year.

11 Apr 2012

Majority of Michigan oncology practices follow treatment guidelines for common cancers

A majority of Michigan oncology practices participating in a statewide consortium followed treatment guidelines for common cancers, but had gaps in managing symptoms and end-of-life care, according to a new study.

11 Apr 2012

Canon, MEDIAN to demonstrate LMS clinical application portfolio at ITEM

MEDIAN Technologies, a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials and clinical routine, announced today it will demonstrate its Lesion Management Solutions -LMS- clinical application portfolio together with Canon at ITEM, April 13-15, 2012 in Yokohama, Japan.

10 Apr 2012

Low-dose spiral CT cost-effective in reducing lung cancer deaths

Lung cancer is the most lethal cancer in the United States. According to the National Cancer Institute, lung cancer causes more than 150,000 deaths annually and has a survival rate of 16 percent. More Americans die of lung cancer each year than of cervical, breast, colon and prostate cancers combined.

10 Apr 2012

MD Anderson initiates Phase 1/2 entinostat-lapatinib ditosylate combination study in metastatic breast cancer

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology have initiated a phase 1/2 study combining Syndax's lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin).

9 Apr 2012

Towards a drug to control cystic fibrosis

Harvard stem cell researchers at Massachusetts General Hospital (MGH) have taken a critical step in making possible the discovery in the relatively near future of a drug to control cystic fibrosis (CF), a fatal lung disease that claims about 500 lives each year, with 1,000 new cases diagnosed annually.

6 Apr 2012

Opportunity for developers and marketers of EGFR inhibitors in Brazil and Mexico

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that patient access to premium-priced targeted cancer treatments in Brazil and Mexico is improving, creating an opportunity for developers and marketers of epidermal growth factor receptor (EGFR) inhibitors.

5 Apr 2012

HSP27 protein can indicate lung damage during early stages of COPD

Chronic obstructive pulmonary disease (COPD) is a widespread disease. In Austria alone, there are between 500,000 and 600,000 sufferers; around ninety per cent of cases are the result of smoking. Now, under the leadership of Hendrik Jan Ankersmit, a research team from the University Department of Surgery at MedUni Vienna and the Christian Doppler Laboratory for the Diagnosis and Regeneration of Heart and Thorax Diseases has discovered a protein marker in the blood that can already indicate lung damage during the early stages of COPD, before a decrease in lung volume is detected by a pulmonary function test.

5 Apr 2012